Andrew Iwach is an Ophthalmology physician affiliated with University of California, San Francisco. OpenAlex indexes 49 publications with 1,163 citations (h-index 20); ClinicalTrials.gov lists 2 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
55 Stevenson St
San Francisco, CA 941052936
Telephone
415-981-2020Registry record last updated 15 Apr 2008.
Clinical trials
- The Efficacy of Selective Laser Trabeculoplasty
Sponsor: Glaucoma Research & Education Group
- Effectiveness of a Procedure for Previously Failed Glaucoma Surgery
Sponsor: Glaucoma Research & Education Group
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
15 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Bausch & Lomb Americas Inc.Program year20255 payments
- NEW WORLD MEDICAL,INC.Program year20252 payments
- Alcon Vision LLCProgram year20257 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Sensory organs
82.3%Prostaglandin Analog30.1%Latanoprost68%Lumigan12%Travoprost6%Zioptan4%Tafluprost4%Iyuzeh3%Travatan Z2%Xalatan2%Part D<11 patientsCarbonic Anhydrase Inhibitor24.9%Dorzolamide-Timolol51%Brinzolamide13%Dorzolamide Hcl13%Simbrinza11%Azopt4%Acetazolamide4%Acetazolamide Er3%Cosopt Pf2%Part D<11 patients+ 8 more classes in this area
Cardiovascular
12%Beta blocker12%Timolol Maleate96%Betaxolol Hcl2%Timoptic Ocudose2%Part D<11 patientsNervous system
1.8%Cholinergic Receptor Agonist1.8%Pilocarpine Hcl100%Part D≥29 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
Similar KOLs
Other experts from the same institution or the same specialty.
Kristine Yaffe, MD
University of California, San Francisco
Peter Carroll, MD
University of California, San Francisco
Mitchel Berger, MD
University of California, San Francisco
Elyse Foster, MD
University of California, San Francisco
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”